NASDAQ:XFOR

X4 Pharmaceuticals Q2 2025 Earnings Results & Report

X4 Pharmaceuticals logo
$3.04 +0.21 (+7.24%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 8, 2025. The company reported EPS of -$3.47 versus the -$4.53 consensus estimate, while revenue of $1.97 million topped the $1.62 million estimate by $350.00 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

X4 Pharmaceuticals EPS Results

Actual EPS
-$3.47
Consensus EPS
-$4.53
Beat/Miss
Beat by +$1.06
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

X4 Pharmaceuticals Revenue Results

Actual Revenue
$1.97 million
Expected Revenue
$1.62 million
Beat/Miss
Beat by +$350.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

X4 Pharmaceuticals Q2 2025 Earnings FAQ

X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$3.47 per share for Q2 2025, beating the consensus estimate of -$4.53. The report was announced on Friday, August 8, 2025.

X4 Pharmaceuticals reported revenue of $1.97 million for Q2 2025, against a consensus estimate of $1.62 million.

X4 Pharmaceuticals Earnings Headlines

Brookline Capital Markets Comments on XFOR FY2030 Earnings
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More X4 Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email.

About X4 Pharmaceuticals

X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body.

Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections.

X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.

View X4 Pharmaceuticals Profile